Clinical Implications of Incorporating Molecular Profiles into the Staging of Endometrial Cancer: A Critical Review of the 2023 FIGO System on the Wave of 2025 ESGO/ESTRO/ESP Guidelines
Simple Summary The present paper reviews the 2023 FIGO staging system for endometrial cancer, which for the first time incorporates molecular testing (like POLE mutations and p53 status) alongside traditional anatomical findings. This update reflects tumor biology and helps avoid over- or under-treating patients, thoug...